{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:42:18Z","timestamp":1787701338869,"version":"build-2784847793"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>We aimed to evaluate the efficacy and safety of Shengxuening (SXN) in treating renal anemia by systematic review and meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, the Cochrane Library, the <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, SinoMed, the China Knowledge Network, the Wanfang Data Knowledge Service Platform and Technology Journal Database were searched from inception to September 2024 randomized controlled trials (RCTs) that compared SXN and other drugs or placebo in treating renal anemia. We used the Cochrane Bias Risk Tool to evaluate the risk of bias of all included RCTs, and used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) to evaluate the certainty of the evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>31 RCTs involving 2,372 patients were included. The efficiency of SXN was superior than the control group (included placebo group, other drugs group) in improving hemoglobin (compared with placebo: MD: 7.15\u00a0g\/L, 95% CI: 5.68\u20138.62, P &amp;lt; 0.001, GRADE: high; compared with other drugs: MD: 6.49\u00a0g\/L, 95% CI: 3.50\u20139.47, P &amp;lt; 0.001, GRADE: very low), serum ferritin (MD: 57.53\u00a0ng\/mL, 95% CI: 29.70\u201385.36, P &amp;lt; 0.001, GRADE: moderate; MD: 28.96\u00a0ng\/mL, 95% CI: 1.88\u201356.04, P = 0.04, GRADE: moderate) and transferrin saturation level (MD: 7.00%, 95% CI: 3.40\u201310.60, P = 0.0001, GRADE: moderate; MD: 3.64%, 95% CI: 1.41\u20135.88, P = 0.001, GRADE: moderate). Besides, the efficiency of SXN combined with other drugs was superior than other drugs group in improving hemoglobin (MD: 11.95\u00a0g\/L, 95% CI: 6.19\u201317.71, P &amp;lt; 0.001, GRADE: moderate), serum ferritin (MD: 53.43\u00a0ng\/mL, 95% CI: 20.65\u201386.21, P = 0.001, GRADE: moderate) and transferrin saturation level (MD: 5.91%, 95% CI: 3.72\u20138.10, P &amp;lt; 0.001, GRADE: moderate). Additionally, the incidence of adverse drug reactions (ADRs) in the SXN group was lower than that in other drugs treatment group (OR: 0.20, 95%CI: 0.12\u20130.33, P &amp;lt; 0.00001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The efficacy of SXN in treating renal anemia is convincing. Compared with other drugs, SXN is comparable or even better in treating renal anemia. Additionally, the safety of SXN is also relatively high.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1510227","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T12:19:53Z","timestamp":1750767593000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of Shengxuening for treatment of renal anemia: a comprehensive systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Li","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ped.12054","article-title":"Iron deficiency anemia and levels of oxidative stress induced by treatment modality","volume":"55","author":"Akarsu","year":"2013","journal-title":"Pediatr. Int. Official J. Jpn. Pediatr. Soc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/MJT.0b013e31825425bd","article-title":"Effect of aggressively driven intravenous iron therapy on infectious complications in end-stage renal disease patients on maintenance hemodialysis","volume":"21","author":"Bansal","year":"2014","journal-title":"Am. J. Ther."},{"key":"B3","first-page":"8","article-title":"Comparison of the therapeutic effects of Shengxuening tablets and ferrous succinate on hemodialysis induced renal anemia","volume":"22","author":"Caixia","year":"2013","journal-title":"China Pharm. Ind."},{"key":"B4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3892\/etm.2016.3307","article-title":"Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients","volume":"12","author":"Cheng","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8796234","DOI":"10.1155\/2019\/8796234","article-title":"Efficacy of SXN in the treatment of iron deficiency anemia: a phase IV clinical trial","volume":"2019","author":"Ding","year":"2019","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ Clin. Res. Ed."},{"key":"B7","first-page":"6","article-title":"Clinical observation of Shengxuening tablets combined with erythropoietin in the treatment of renal anemia in hemodialysis patients","volume":"39","author":"Fan","year":"2017","journal-title":"Hubei J. Traditional Chin. Med."},{"key":"B8","first-page":"285","article-title":"Observation of the therapeutic effect of Shengxuening in the treatment of renal anemia in non dialysis patients with chronic kidney disease","volume":"15","author":"Guo","year":"2015","journal-title":"J. Clin. Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.23876\/j.krcp.20.020","article-title":"Drug treatment patterns and work productivity in chronic kidney disease patients with anemia in China: cross sectional analysis of real-world data","volume":"39","author":"Haalen","year":"2020","journal-title":"Kidney Res. Clin. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1111\/hdi.12567","article-title":"HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism","volume":"21","author":"Haase","year":"2017","journal-title":"Hemodial. Int. Int. Symposium Home Hemodial."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e46737","DOI":"10.7759\/cureus.46737","article-title":"Anemia and hypoxia impact on chronic kidney disease onset and progression: review and updates","volume":"15","author":"Habas","year":"2023","journal-title":"Cureus"},{"key":"B12","first-page":"53","article-title":"Observation of the effect of Shengxuening tablets combined with Rosuvastatin capsules in the treatment of renal anemia in patients with chronic kidney disease stage 4-5","volume":"34","author":"Huang","year":"2022","journal-title":"J. Jiangxi Univ. Traditional Chin. Med."},{"key":"B13","first-page":"170","article-title":"Prevention and treatment of shengxuening on renal anemia and chronic renal injury of iron overload in mice","volume-title":"Journal of Henan University","author":"Jiahuan","year":"2017"},{"key":"B14","first-page":"62","article-title":"Clinical observation of Shengxuening in the treatment of renal anemia in chronic kidney disease","volume":"30","author":"Kang","year":"2020","journal-title":"Chin. Health Nutr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1111\/hdi.12553","article-title":"Oral iron supplementation: potential implications for the gut microbiome and metabolome in patients with CKD","volume":"21","author":"Kortman","year":"2017","journal-title":"Hemodial. Int. Symposium Home Hemodial."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1476","DOI":"10.1016\/S2214-109X(19)30414-0","article-title":"Iron-deficiency anaemia in pregnancy: the role of hepcidin","volume":"7","author":"Lewkowitz","year":"2019","journal-title":"Lancet. Glob. Health"},{"key":"B17","first-page":"2","article-title":"The effect of Shengxuening tablets combined with ferrous succinate tablets on the dosage of erythropoietin and iron metabolism indicators in patients with non dialysis chronic kidney disease and renal anemia","author":"Li","year":"2021","journal-title":"Chin. Sci. Technol. J. Database Med. Health"},{"key":"B18","first-page":"2","article-title":"Comparison of the therapeutic effects of Shengxuening tablets and ferrous sulfate on renal iron deficiency anemia","author":"Li","year":"2009","journal-title":"Chin. Health Nutr."},{"key":"B19","first-page":"247","article-title":"Clinical efficacy study of Shengxuening tablets combined with rosuvastatin in the treatment of renal anemia","volume":"40","author":"Liu","year":"2022","journal-title":"Chin. J. Traditional Chin. Med."},{"key":"B20","first-page":"1096","article-title":"Clinical observation of Shengxuening tablets in reducing the risk of micro inflammation during maintenance hemodialysis treatment of renal anemia","volume":"27","author":"Liu","year":"2016","journal-title":"Chin. Pharm."},{"key":"B21","first-page":"406","article-title":"Clinical analysis of Shengxuening combined with L-carnitine in the treatment of renal anemia in hemodialysis patients","volume":"15","author":"Liu","year":"2015","journal-title":"J. Clin. Nephrol."},{"key":"B22","first-page":"504","article-title":"Clinical observation of Shengxuening tablets in the treatment of renal anemia in non dialysis patients with chronic kidney disease","volume":"28","author":"Long","year":"2012","journal-title":"J. Changchun Univ. Traditional Chin. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5414\/cn107309","article-title":"Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease","volume":"77","author":"Martinez-Vea","year":"2012","journal-title":"Clin. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1021\/jf903177q","article-title":"In vitro bioavailability of iron from the heme analogue sodium iron chlorophyllin","volume":"58","author":"Miret","year":"2010","journal-title":"J. Agric. food Chem."},{"key":"B25","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"3","author":"Moher","year":"2009","journal-title":"Indep. Open-Access J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/bip.20173","article-title":"Human serum albumin complexes with chlorophyll and chlorophyllin","volume":"77","author":"Ouameur","year":"2005","journal-title":"Biopolymers"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7692376","DOI":"10.1155\/2020\/7692376","article-title":"The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes-A systematic literature review","volume":"2020","author":"Palaka","year":"2020","journal-title":"Int. J. Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis","volume":"52","author":"Rozen-Zvi","year":"2008","journal-title":"Am. J. kidney Dis. official J. Natl. Kidney Found."},{"key":"B29","article-title":"Curative effect of SXN tablets combined with ferrous succinate tablets on patients with iron deficiency anemia during pregnancy","author":"Sheng-Ming","year":"2018","journal-title":"Prog. Mod. Biomed"},{"key":"B30","first-page":"248","article-title":"Observation of the therapeutic effect of Shengxuening on renal anemia in hemodialysis patients","author":"Shi","year":"2019","journal-title":"Famous Dr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ Clin. Res. Ed."},{"key":"B32","first-page":"91","article-title":"Clinical study on the treatment of renal anemia in maintenance hemodialysis patients with Shengxuening combined with recombinant human erythropoietin","volume":"54","author":"Sun","year":"2022","journal-title":"New Tradit. Chin. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.freeradbiomed.2015.04.007","article-title":"Amelioration of radiation-induced hematopoietic syndrome by an antioxidant chlorophyllin through increased stem cell activity and modulation of hematopoiesis","volume":"85","author":"Suryavanshi","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0280817","DOI":"10.1371\/journal.pone.0280817","article-title":"Anemia and its predictors among chronic kidney disease patients in Sub-Saharan African countries: a systematic review and meta-analysis","volume":"18","author":"Taderegew","year":"2023","journal-title":"PLoS One"},{"key":"B35","first-page":"37","article-title":"Clinical effect analysis of Shengxuening in the treatment of 58 cases of renal anemia","volume":"8","author":"Tan","year":"2013","journal-title":"Natl. Med. Front. China"},{"key":"B36","first-page":"27","article-title":"Clinical observation of Shengxuening combined with erythropoietin in the treatment of chronic renal failure and renal anemia","volume":"11","author":"Tang","year":"2011","journal-title":"Pract. Integration Traditional Chin. West. Med. Clin. Pract."},{"key":"B37","first-page":"45","article-title":"Observation on the effect of Shengxuening tablets combined with rosuvastatin in the treatment of renal anemia","volume":"45","author":"Tang","year":"2023","journal-title":"Hubei J. Traditional Chin. Med."},{"key":"B38","first-page":"316","article-title":"Clinical efficacy of Shengxuening tablets in patients with non dialysis chronic kidney disease and renal anemia","volume":"41","author":"Tang","year":"2019","journal-title":"Traditional Chin. Pat. Med. Simple Prep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11596-020-2179-z","article-title":"Effect of sheng xue ning tablets on renal anemia in patients subject to maintenance hemodialysis and safety evaluation: a multi-setting prospective randomized study","volume":"40","author":"Tang","year":"2020","journal-title":"Curr. Med. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0117383","DOI":"10.1371\/journal.pone.0117383","article-title":"Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis","volume":"10","author":"Tolkien","year":"2015","journal-title":"PLoS One"},{"key":"B41","first-page":"70","article-title":"Clinical study on the adjuvant treatment of renal anemia in maintenance hemodialysis patients with Shengxuening","volume":"14","author":"Wang","year":"2013","journal-title":"Chin. J. Integr. Traditional Chin. West. Med. Nephrol."},{"key":"B42","first-page":"128","article-title":"Observation of the therapeutic effect of Shengxuening as an adjuvant therapy for 44 hemodialysis patients with renal anemia","volume":"26","author":"Xu","year":"2012","journal-title":"Prim. Healthc. China"},{"key":"B43","first-page":"900","article-title":"Clinical observation of Shengxuening tablets in the treatment of renal anemia in chronic kidney disease","volume":"29","author":"Xu","year":"2018","journal-title":"Mod. Diagnosis Treat."},{"key":"B44","first-page":"3050","article-title":"Shengxuening tablets were used to treat 58 cases of chronic kidney disease complicated with renal anemia","volume":"35","author":"Yi","year":"2015","journal-title":"Henan Tradit. Chin. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11655-012-1210-z","article-title":"Effects of sodium copper chlorophyllin on mesenchymal stem cell function in aplastic anemia mice","volume":"19","author":"Yin","year":"2013","journal-title":"Chin. J. Integr. Med."},{"key":"B46","first-page":"1495","article-title":"The therapeutic effect of Shengxuening tablets on renal anemia in patients with chronic renal failure and uremia","volume":"28","author":"Zeng","year":"2022","journal-title":"Chin. J. Drug Abuse Prev. Treat."},{"key":"B47","first-page":"678","article-title":"Clinical study on the treatment of renal anemia with Shengxuening tablets combined with erythropoietin and L-carnitine","volume":"31","author":"Zeng","year":"2016","journal-title":"Mod. Drugs Clin. Pract."},{"key":"B48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2478\/jtim-2020-0037","article-title":"Shengxuening versus oral iron supplementation for the treatment of renal anemia: a systematic review","volume":"8","author":"Zeng","year":"2020","journal-title":"J. Transl. Int. Med."},{"key":"B49","first-page":"481","article-title":"Effect of Shengxuening tablet combined with erythropoietin on renal anemia in patients with stage V diabetes kidney disease","volume":"15","author":"Zhang","year":"2015","journal-title":"J. Clin. Nephrol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/s0254-6272(16)30077-2","article-title":"Effect and safety of Shengxuening (extract from excrement of bombyxin) for renal anemia: a systematic review","volume":"36","author":"Zhang","year":"","journal-title":"J. Tradit. Chin. Med."},{"key":"B51","first-page":"110","article-title":"Clinical observation of Shengxuening tablets in maintenance hemodialysis patients with renal an emia and improve iron metabolism of blood","volume":"16","author":"Zhang","year":"","journal-title":"J. Clin. Nephrol."},{"key":"B52","first-page":"2","article-title":"A clinical randomized controlled trial of Shengxuening tablets combined with recombinant human erythropoietin in the treatment of mild to moderate renal anemia","volume":"19","author":"Zhang","year":"2010","journal-title":"Chin. Health Care"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1029641","DOI":"10.3389\/fphar.2022.1029641","article-title":"The efficiency and safety of Shengxuening tablet on treating and preventing iron deficiency anemia: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B54","first-page":"116","article-title":"Observation of the therapeutic effect of Shengxuening tablets in reducing the risk of micro inflammatory reactions during maintenance hemodialysis treatment of renal anemia","volume":"41","author":"Zhong","year":"2020","journal-title":"Jilin Med."},{"key":"B55","first-page":"3777","article-title":"The clinical observation of ferrous succinate and Shengxuening in adjuvant treatment of renal anemia in peritoneal dialysis patients with diabetes nephropathy","volume":"27","author":"Zhou","year":"","journal-title":"Chin. Pharm."},{"key":"B56","first-page":"5383","article-title":"Effect of Shengxuening tablet on renal anemia in peritoneal dialysis patients with diabetes nephropathy","volume":"36","author":"Zhou","year":"","journal-title":"Chin. J. Gerontology"},{"key":"B57","first-page":"93","article-title":"Observation of the effect of Shengxuening tablets combined with erythropoietin in the treatment of renal anemia in maintenance hemodialysis patients","volume":"18","author":"Zhou","year":"2009","journal-title":"Chin. J. Clin. Med. Health Nutr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1510227\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T12:19:59Z","timestamp":1750767599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1510227\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":57,"alternative-id":["10.3389\/fphar.2025.1510227"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1510227","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"article-number":"1510227"}}